Product Description
Pneumococcal Conjugate Vaccines
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: EpicentRx
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Pneumonia, Pneumococcal|Malnutrition|Communicable Diseases|Pneumococcal Infections
Phase 3: Sneezing|Influenza, Human|Meningitis, Haemophilus|Vision, Low|Nasopharyngeal Diseases|Meningitis, Pneumococcal|Acute Respiratory Distress Syndrome|Maternal Death|Pneumonia, Pneumococcal|Measles|Pneumonia|Meningitis|Otitis Media|Sepsis|Bacteremia
Phase 2: HIV Infections|Pregnancy Outcomes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
fPCV | P4 |
Active, not recruiting |
Malnutrition|Pneumonia, Pneumococcal |
2023-05-31 |
|
PCV1+1_FU | N/A |
Completed |
Meningitis|Pneumonia |
2022-12-01 |
|
FPCV | P4 |
Active, not recruiting |
Pneumonia, Pneumococcal|Communicable Diseases|Pneumococcal Infections |
2022-09-30 |
|
PICRcarriage | N/A |
Unknown status |
Pneumonia, Pneumococcal |
2020-08-01 |